Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioFocus, Ono in Drug Discovery Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

BioFocus, Ono in Drug Discovery Pact

Will focus on CNS Disorders

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ono Pharmaceutical has entered a collaboration with BioFocus, the service division of Galapagos NV, for the discovery of novel drugs in the field of CNS disorders. BioFocus will use its drug discovery platform to deliver leads and clinical candidates to Ono. Financial details were not disclosed.
 
“We are delighted to have this new agreement, which is the first drug discovery program with this, a most valued, client,” said Dr. Chris Newton, senior vice president of Galapagos Services and managing director of BioFocus. “This project plays to BioFocus historic strengths and the expanding breadth and depth of this partnership is testament to a tried and trusted relationship.”
 
Kazuhito Kawabata, Ph.D., Member of the board of directors, executive officer and executive director, Discovery and Research of Ono, said, “We have the highest regard for the BioFocus’ comprehensive drug discovery platform. This collaboration will strengthen Ono’s drug discovery capability in the field of CNS disorders with significant unmet medical needs and we are expecting that innovative drugs will be created through this collaboration.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics